James Cabrera
Host, Hayden Vesta Relations
Replay available
Delcath Systems (NASDAQ:DCTH) Q3 2020 earnings call, held 2020-11-11. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/delcath-systems-inc-dcth-q3-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Greetings, and welcome to the DelCath Systems Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, James Cabrera of Hayden Vesta Relations, Thank you, sir. You may begin.
0:32 Thank you. And once again, welcome to Delcath Systems' third quarter 2020 earnings call. With me on the call are Gerard Michel, Chief Executive Officer, John Papora, Chief Operating Officer, Dr. Johnny John, VP Medical Affairs, and Christine Padula, Principal Accounting Officer. I'd like to begin the call by reading the Safe Harbor Statement. This statement is made pursuant to the Safe Harbor for Forward Looking Statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
1:18 Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, It makes no assurances that such expectations will prove to have been correct. Actual results may differ materially from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those expressed or implied in the forward-looking statements, please see risk factors detailed in the company's annual report on Form 10-K. Those contained in subsequently filed quarterly reports on Form 10-Q as well as in other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this earnings call are made only as of the date of this call. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events, or circumstances.
2:14 Now I would like to turn the call over to Gerard Michel. Gerard, please proceed.
2:20 Thank you everyone for joining today. As many of you know, this is my first earnings call since joining Dell Cath in October. In addition to the expected updates on clinical progress and financial results, I will first explain why I found the Dell Cath opportunity so compelling that I chose to join the company. I think this will be useful for investors to know the story well and especially valuable for the many investors who are either looking at the story for the first time or taking a second look after ceasing to follow the company years ago. An obvious first question when looking at any opportunity, whether a career move or an investment opportunity, is whether the company is offering or developing a product or service that addresses a real unmet need. I believe that DELFCAP clearly has such a product. The drug-device combination, MELP1-HDS, and the standalone CE-Mark device, Chemosat, available in the EU, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated effects. The lead indication is metastatic ocular melanoma, and while an orphan indication, with an estimated 1,200 to 1,500 patients a year in the U.S., there is no standard of care, and the existing treatments have not been shown to offer significant benefit to patients.
3:30 Upon diagnosis of liver metastases, patients have a very poor prognosis from this devastating disease. While it is clear that there is an unmet need, the next key question is whether the ongoing focus trial would demonstrate adequate efficacy. The trial's primary endpoint is overall response rate. In our submission to the FDA, we based the outcome of the trial on the hypothesis that melphalan HDS is more efficacious than immune oncology agents, one category of treatments frequently used in patients with metastatic ocular melanoma, given their approved label for metastatic melanoma. For analytical purposes, the FOCUS trial should demonstrate an overall response rate of at least 21% to show superiority over the response rate calculated from a meta-analysis that was conducted on immuno-oncology trials in metastatic ocular melanoma.
4:23 It is important to note that all previously published studies, even the first pivotal trial with the first-generation filter, exceeded this targeted overall response rate. In these studies, the overall response rates have varied from 27% to 72%. with the last three studies using the second generation device ranging from 47% to 72%. While these last three published studies were all single or dual center studies, which often have higher response rates, and the last study focused on earlier stage patients who generally seem to have a better response rate, we do fully expect the trial results to be somewhere within the range of all four studies and be well in excess of the 21% target overall response rate. All of this information was critical to my conclusion that DelCath is nearing the end of a development program which leads to an efficacious product addressing an unmet need.
5:16 While the lead indication is an ultra-orchid indication, we believe methyl and HDS will eventually have a role in treating other solid tumors of the liver in the U.S., as it already does in the EU. In addition to ocular melanoma, the liver is the predominant site of metastasis for colorectal cancer and gastrointestinal neuroendocrine tumors. Complete surgical resection might represent a curative option in patients with isolated hepatic metastases, but resection is not possible in most patients because of the number, location, or size of the hepatic metastases. Hepatic metastases can also co-occur with many other malignancies, such as breast cancer, renal cell carcinoma, cutaneous melanoma, and soft tissue sarcoma. Liver is often the life-limiting organ for cancer patients, and overall survival is usually under 12 months.
6:06 There have been a variety of studies and case reports in many of these tumor types that support further investment to investigate the possible efficacy of melphalan HDS in a broader set of tumor types, thereby dramatically expanding the market potential for melphalan HDS. Of course, turning this potential into reality will take time, and the first step is approval in a single indication, which is currently our primary focus. A second critical factor, which I examined carefully before deciding to join DELCATH, is whether there is adequate evidence to conclude that the safety of the second-generation melphalan HDS device is meaningfully improved over the device studied in the pivotal trial conducted 10 years ago. In that trial, four deaths occurred due to the treatment, and despite clear signals of efficacy, the risks associated with the device led the FDA to conclude that the benefits of the product did not outweigh the risks with the first-generation product.
7:01 The safety issues were multifactorial, but there were two that are most noteworthy. The first was patient selection. In the first pivotal trial, many patients had extensive liver disease and were not restricted by volume of tumor burden in the liver. These patients accounted for a disproportionate percentage of the adverse events. We now know that, like most chemotherapeutic regimes, some patients are just too sick to tolerate treatment. Patients were treated in the first pivotal trial that would have been excluded from many other liver-directed therapies and systemic hemotherapeutic agents. A second and perhaps most important change was improving the filtration efficiency and consistency. The previous generation filter, whose manufacturer was outsourced, was inconsistent in its filtration efficiency and had an unacceptable rate of hematological toxicities due to both the design of the filter and inadequate manufacturing controls.
7:54 To this end, the company changed the design of the filter, insourced manufacturing the filter and develop validated physical and functional release specifications for the filter and its critical sub-components. The evidence for the improved safety is again in the public domain. I will not go through the safety findings of each of the three published studies mentioned previously, but I will mention results from the most recent study from Leiden University Medical Center. In a publication reporting the results of the study, the authors noted that all the adverse events were well manageable or self-limiting and there were no treatment-related deaths. The investigators also noted that the hematologic and hepatic toxicity percentages were significantly lower compared to studies using the earlier generation of chemosat, which utilized a different filter system. Finally, based on a validated quality of life tool used in the trial, the investigators concluded that chemosat is well tolerated with maintenance of quality of life with only a mild and temporary impairment of physical functioning noted six weeks after the second chemosat treatment.
8:55 It is important to note that there is not but a single treatment-related death in over 1,000 treatments in Europe, and that in the FOCUS trial, which still has nine patients undergoing treatments, 356 treatments have been given to 91 patients, and we can confidently state that the adverse event profile is within the ranges seen in the published studies. This study is utilizing an independent data safety monitoring board, which is met seven times as planned during the course of the trial. and there has never been a need to pause the trial for reasons of unacceptable safety risk or a safety concern. In summary, given the totality of the safety and efficacy data available, I reach the conclusion that the FOCUS trial is likely to produce the data necessary to support a compelling case that Delcas Melphalan HDS has a high probability of approval to treat metastatic ocular melanoma.
9:44 And given the multiple smaller studies and case reports on other tumor types, Melflin HDS has significant potential to expand into larger markets over time. While compelling, that in itself was not adequate to convince me to join DELFCAP. Beyond just the data, an important question is whether the team is in place to execute. While the team is lean and key positions need to be filled, John Purpura, our COO, and Johnny John, Dr. Johnny John, our Vice President of Clinical and Medical Affairs, have done an excellent job planning and executing on all aspects of the development program. including manufacturing, process validation, regulatory strategy, and clinical development. I would not have joined if I was not confident in their capabilities. In addition, we have a strong, experienced, and reinvigorated board with a wealth of experience supporting the management team.
10:36 Since my arrival, John Papora, Johnny John, and I have set the company's near-term priorities as follows. One, complete the FOCUS trial and submit an approvable NDA. prepare for the commercialization of melphalan HDS in the United States. Three, raise the awareness of Delcath in the investor community. Four, prioritize additional indications for melphalan HDS and then design and execute a development plan for the higher value indications. I will touch briefly upon each of these priorities. Starting with the FOCUS trial and NDA submission, Delcath enrolled and started treating the final patient October 2nd, 2020. The next milestone is the release of top-line data, which we will project will occur early in 2021.
11:21 In that release, we intend to share the primary endpoint, overall response rate, as well as duration of response and an evaluation of safety. We are currently projecting submission of the NDA to the FDA in the first quarter of 2022, which would still allow for a 2022 launch. The primary gating item to our submission is data monitoring, which requires site access. Due to the increased rates of COVID-19 cases, many sites have recently increased access restrictions. While we are utilizing remote monitoring where feasible, not all sites are equipped to support remote monitoring, and not all data can be remotely monitored. In addition, when lockdowns end, the number of days of access is being reduced due to the high demand from multiple sponsors.
12:09 Our projections assumes that current and future access restrictions are limited in duration to a few months. Given the rapidly changing landscape, it is difficult to project a submission date with a high degree of confidence, and our assumptions could prove to be overly optimistic or pessimistic. In an effort to minimize further delays, we are attempting to negotiate increased site access when restrictions are lifted, and also intend, subject to FDA feedback, to adjust our monitoring plans to focus on the CRF pages most important to the efficacy and safety endpoints. a strategy which we believe is consistent with current FDA guidance on monitoring. I must stress that the team's focus is not primarily speed, but quality. Our goal is not to submit an NDA as quickly as possible, but to submit an approvable NDA in a timely manner.
12:58 Regarding the second priority, commercialization planning is underway, with a well-known consulting firm helping lay the groundwork to ensure appropriate patient access and reimbursement. In addition, we expect to announce some significant hires over the coming few months in commercial roles. One small but exciting step towards commercialization is the choice of a trade name. In September, the FDA conditionally accepted the name Hepzado kit for use in the U.S. Going forward, we will use Hepzado or Hepzado kit when referring to melphalan HDS, the combination drug device product. I look forward in the coming quarters to providing additional updates and details on our prelaunch activities. Our third priority is to raise awareness with the investor community. Delcath has not received much attention for many years for a variety of reasons.
13:46 It is not the first company that has had some missteps, been forgotten, and then continued to be overlooked despite mounting evidence of significant progress and value creation. To raise awareness, Delcath will need to deliver on its milestones, and the management team will need to be transparent with and accessible to the investor community. To that end, I plan on getting out on the virtual road on a regular basis and maintaining an open and, of course, Reg FD compliant line of communication with our current and potential shareholders. Consistent with our efforts to raise awareness, last week we hosted a key opinion leader call with Dr. Mark Bergmans, head of interventional radiology at the Leiden University Medical Center in the Netherlands, an investigator in the study I previously mentioned, which studied the use of chemosat in earlier stage ocular melanoma patients.
14:34 Our fourth strategic priority is the prioritization of additional indications for HEP-SATO and the subsequent design and execution of development plans for the higher value indications. Over the next six months, we'll review the incidence, unmet need, available efficacy data, and development requirements for a broad set of liver cancers in order to select a portfolio of follow-on indications which will maximize the value of HEP-SATO and CHEMOSAT platform. A key part of that process will be to convene disease-specific advisory boards to ensure that we choose the highest potential indications and, as importantly, the optimum development plan. In 2017, we initiated the ALIGN trial, a global phase three clinical trial for intrahepatic cholangiocarcinoma based on promising data generated from commercial treatments in Europe.
15:24 Presently, we have paused our work on the ALIGN trial while we revisit the protocol to determine changes which may boost recruitment rates. In the interim, the clinical team is focusing its efforts on the focused trial conclusion and subsequent NDA filing. In summary, I believe Hepzado is a clinically differentiated, high-value platform with the potential to address multiple cancer indications of high unmet medical need. I am committed to leading the organization towards its goal of making Hepzado the first product specifically labeled for metastatic ocular melanoma patients a population which currently has limited therapeutic options. I look forward to building shareholder value both through the successful commercialization of HipsAuto and metastatic ocular melanoma and longer term initiating additional targeted clinical programs to expand the market opportunity of this platform technology.
16:13 I look forward to taking your questions, but first we'll turn the call over to Christine to review the financials.
16:19 Thank you Gerard and good morning to everyone. Our product revenue for the three months ended September 30, 2020 was approximately $340,000 compared to the $216,000 for the prior year period from our sales of Chemosat procedures in Europe. Selling general and administrative expenses were approximately $2 million compared to $4 million in the prior year quarter. Research and development expenses for the third quarter were $3.3 million compared to 1.8 million dollars in the prior year quarter. Total operating expenses for the third quarter were 5.3 million dollars compared to the 5.8 million dollars in the prior year quarter.
17:07 We recorded a net loss for the three months ended September 30th, 2020 of 5 million dollars compared to the net loss of 7.5 million dollars for the same period in 2019. At September 30th, we had cash, cash equivalents, and restricted cash totaling $11.1 million compared to cash, cash equivalents, and restricted cash of $10.2 million at December 31st, 2019 and $15.5 million at the end of September 30th, 2019. During the three months ended September 30th, 2019, and September 30, 2019, we used $5.2 million and $12.4 million, respectively, of cash in our operating activities.
18:03 That concludes my financial remarks, and I now ask the operator to open the phone lines for Q&A. Operator, can you please poll for questions? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Thank you. Our first question comes from the line of Scott Henry with Roth Capital. Please proceed with your questions.
18:48 Thank you, and good morning. A lot of new information on the call. I did just have a couple questions. First, 91 patients for 356 treatments. It's about 3.9, or call it four cycles per patient, which would seem to be an encouraging sign. How would you kind of interpret that, in your opinion?
19:16 Well, I think it means, just using the simple math, that on average patients are getting about four treatments. And as you know, it's six to eight weeks per protocol per treatment. So that's an encouraging sign. I don't want to go beyond that and say, hey, look, it's, you know, impute an overall response rate from that. But certainly if you assume that most of those patients are getting a response and it's not just stable disease, It's very, very encouraging.
19:47 Okay. I would certainly agree. And then with the data coming in early 21, in a filing coming in early 22, what's kind of the gating factor?
20:00 Yeah, the gating factor is really monitoring. You know, we have probably a disproportionate number of patients in a handful of sites that with, you know, the monitoring is certainly backed up through COVID, and it's really working through that. And the slowest site with the most data is the gating item. So we might have, you know, 17 out of, I think it's 20 sites, give or take, done, and it might be two or three that are dragging us that far along. We're certainly doing everything we can to accelerate that. But when you do the math at the pace and the access you have, and remember, it's us and umpteen other sponsors trying to get in the door and negotiate for additional access.
20:52 And some of these sites are saying, you know, all we're going to do is scan for your redact and redact and scan, excuse me, paper copies and send them off to you. And you only get one person every two days a month to do that because every other sponsor is asking for it. That's one example. Another is when they open up, it could be normally you could have three or four people show up. They only let two because they're trying to do distancing. There's a myriad of things like that, but all under the same basic theme of when things open up, they're not totally opened up. And then things start shutting down like they are now. We have to make some set of assumptions about how long will they be shut down. So it's a handful of sites that we're trying to pull the data through a thin straw is the best way to think about it.
21:39 Okay, and I very much appreciate the guidance of at least 21%. Now, how comfortable are you that that bar hasn't shifted since you last met with the FDA? I mean, has the kind of standard of care improved at all, or would you say it's similar to when you came across that
22:05 I don't think anything dramatic has changed since then, but I'll ask Johnny John to comment.
22:13 Sure. Thank you, Scott, for the question. We're not that concerned that this bar has shifted. This was a meta-analysis done on 16 publications at the time to get the overall response rate in those publications and establish a baseline or a minimum that we would have to hit to show superiority over. Immuno-Oncology Treatments. Even if it did shift a small amount, it still is not of a concern currently to us. But, you know, if we would, of course, consider any new publications and we could do an analysis internally to see if those would impact the current 21%. But again, we're not deeply concerned by a small shift in that number.
23:01 Okay, great. Well, thank you for taking the questions, and thank you for the increased visibility. Our next question comes from the line of Yale Chen with Laidlaw & Company. Please proceed with your question.
23:18 Good morning, and thanks for taking the questions, and Gerard, congrats on this great opportunity. My first question is that you still have nine patients under treatment. Do you get some sense when those treatments will be completed? Any comments on those patients? And when you say report the top line data for early 2021, would that be first quarter? Then I have some follow-ups.
23:49 Sure. Let me start with the second question. It will be in the first quarter and then hopefully early in the first quarter. We need to give ourselves a little bit of room, so we'll say the first quarter. In terms of the nine patients, we don't know when they'll be completed. It depends on how many cycles of treatment they get. We did mention the last patient was dosed, I think, in September, started dosing. Now, if it happens that we have all the data in except for, let's say, two or three patients, We'll give the top line data, and then we'll just say that, you know, except for X number of patients who were not available at this time, which is not unusual, as you know, in oncology trials.
24:34 So that will not be a gating item to getting top line data out.
24:39 Okay. And you mentioned about the 21% for the immuno-oncology agents. And are none of those agents actually formally approved for the metastatic treatment? Oculomelanoma. Is that correct or that's actually somewhat has been approved?
24:57 Well, somewhat has been approved. I'll let Johnny John explain the kind of the unique situation of those agents.
25:04 Sure. So those agents have been approved, Yilgen. The analysis, meta-analysis was done on both single therapy agents but also combination therapy regimens that were used for metastatic melanoma. So in terms of the approval, the approval for these agents are overall for metastatic melanoma. They didn't specify whether this related to cutaneous or ocular. But if you look at the data provided to the FDA for the approvals, there are no patients with ocular melanoma included in that data. So the majority of patients that were analyzed for supporting this approval came from cutaneous treatment by immunotherapy agents. but to answer your question, it was a combination of approved single agent and multiple combination therapy studies that we looked at for the meta-analysis.
26:01 Okay, great. Maybe my last question here is that based on the last USAID-3 study in terms of the response rate, do you feel that if The FOCUS study has something similar to that, this commercially verifiable product, or any sort of thoughts or comments on this issue? And thanks.
26:29 Yeah, that's a good question. I mean, if it sails over the bar but only by inches, which I don't think will be the case, but if that was the case, then I still think it would be commercially viable. The immuno-oncology agents have single-digit, if even response rates, so we would be far better than that. And then the other liver directed therapies don't have a lot of published data at all in this area, so there's really nothing to point to. Now, you know, it's always best to have a bigger number, and that would be helpful, but I do think that any approval in this area with data that shows As a reminder, if you would like to ask a question, press star 1 on your telephone keypad.
27:38 Our next question comes from RK with HC Wainwright. Please proceed with your question. Thank you. Good morning, Gerard and Johnny John. Gerard, congratulations. You're taking reins of DELCAT after having a successful run as CFO at VeriCell, which also went through a makeover. What are the learnings there that you would like to bring over to DELCAT?
28:08 Well, I wasn't expecting that question, R.K., but thanks for asking that. The learnings from Veracel, I think a couple things. One is I'll say the truth will set you free. It's good to always have an open conversation about barriers, obstacles, and address them head-on, both within the management team and then in a thoughtful manner and the right time with investors. So there's never, you know, in this area, there's never a straight line between here and there. There are going to be curves and detours. I think, you know, everyone needs to take those into account and have constructive dialogue. So transparency both internally and then, again, it's a little more stringent and regulated but also with the investor community.
28:55 That's important. I think the second is, you know, trust your team. Give them solid directions and a direction to go and let them run. with the appropriate QCing and Saturday checking. And the third is having the right balance between having very specific goals in mind but recognizing that at times you'll have to be flexible and deviate from them. And that's probably the toughest part because, again, unanticipated things will occur at times. So that's kind of a balancing act. So I think I'd leave it at those three lessons. Great. Certainly, I wish you all success here. A couple additional questions.
29:49 It's interesting. This technology is interesting that the company utilizes to deliver melphalan, which is a well-known and well-understood drug. What is novel about this technology in the sense of You know, is it something easy for some of these surgeons to conduct? And also, is there a learning curve for the surgeons to use this technology? Would that be any hindrance at all, or is this something that is easy for these folks to use in their OR?
30:31 Okay, R.K., I think there are really two parts to your question. What's novel about the technology and then the learning curve in the surgeons? I'm going to ask our COO, John Padora, to discuss about what's novel about the technology, and then Johnny John can talk through the learning curve and radiology. So, thank you, Gerard.
30:49 I think what's novel about this technology can be summed up in three words, and you might have seen this in various incarnations in our prior communications, but radiology the concept of isolation, saturation, and filtration. That's what's novel. Taken together, we can isolate an organ and because of that isolation technique really ramp up the dose of chemotherapy because you can have the dose of chemotherapy be much more effective in higher doses and yet spare the patient from the systemic side effects. And then of course there's the filtration technique which comes after the dosing and returns the blood to the patient with the significant amount of chemotherapy removed.
31:34 So those are the three tenets of the technology which sound very simple. In practice, there's an orchestration of the various participants conducting the surgical procedure and Yes, there's a learning curve, but each individual practitioner runs the procedure as an orchestrated event, and we have several centers now around the world that have conducted well over 100 treatments, and these things get shorter and shorter in time, and the procedure becomes more and more routine. So we're confident that we'll be able to build the commercial organization around that concept of having Specialized Centers conduct the procedure as a matter of routine.
32:19 Let me ask Johnny John to talk to you about the experience in Europe on the commercial setting in terms of getting centers up and running and familiar with the technique.
32:31 Sure. Thank you, Gerard. So I would just go on top of what John said. There is a learning curve. We are very familiar with what it takes to get up a new site to get them up and running. We do have a comprehensive training program in place, which constitutes of a first part of didactic training and then additional proctoring that takes place for each member of the procedural team that will conduct the procedure. We don't find that individually the tasks required to do the procedure are inherently difficult. It's the combination of the whole team working together, as John said, as an orchestra. while performing the procedure that requires some skill set and some training. So we usually do have a set of proctors that will be available and present when a new site comes up and running.
33:25 And this would be an individual proctor for each member of the procedural team that is taking place in the new center. We do encourage and have these centers go and visit and see a procedure prior to that at a trained site. so that they have additional familiarity on how the procedure is conducted. So, so far, we haven't had any issues. And again, as John has said, we've had centers that have conducted over 100, and we've had centers that have conducted over 200 procedures. You know, obviously, like anything else, the more procedures you conduct, your familiarity and skill sets, of course, improve. Fantastic. Thank you, gentlemen. And then the last question from me is, obviously, there are multiple indications where I can think You know, you would need, it's helpful, you know, to target a large bolus of drugs.
34:20 What other indications would Delgat be looking at, you know, once you get through the current indication of metastatic ocular melanoma? I know you listed a few of them on your slide deck, but I'm just trying to see... As you regroup, what are the indications that seem most viable and quick to the market?
34:51 Well, quick to the market, you touched on an important point there. There are multiple inputs to trying to decide which to go after first or in parallel. Obviously, unmet need. both, you know, are there alternative therapies and how many patients are there? What type of evidence do we have that it's likely to work? And, you know, we have lots of individual case studies and small reports out of Europe for most of those cancers that we mentioned. Then third is the cost to get a label expansion and or get reimbursement. You know, I think it'll be some mix, and it may frankly be all, but just staggered in terms of the of ICC, which the trial is open, but frankly, recruitment has been very slow due to some inclusion and exclusion criteria that perhaps we will change. Neuroendocrine, where we have some fairly solid data from an earlier trial, where it was a mix of different tumor types treated.
35:52 Breast, where we've heard of some very good reports out of Europe, single cases. And then colorectal, where just simply given the size of that indication, makes sense to explore. I think that's the set that we'll choose from, and it could very well be that something in a year and a half from now we have something going on in three or four of those, or maybe even four on a really upside scenario in terms of funding and resources. But I think over time, both whether you look at compendia and various guidelines and label expansion, This product will be used across multiple tumor types. Again, it's a stepwise fashion. We've got to have the first one approved and start developing efforts in others. But we will do that. And I think the four I mentioned, some subset of those will be the next ones we start.
36:49 Thank you. Thank you, Gerard. And thank you, gentlemen, for taking all my questions. And we'll talk to you soon.
36:55 Take care. Thanks, RK. Our next question is a follow-up from Yale Jen with Laidlaw. Please proceed with your question.
37:05 Thanks for taking the follow-up. Just a very quick one. As far as now, there's still no deaths occurred in the FOCUS study. Is that correct?
37:18 Yes, that is true. Treatment-related, yes.
37:22 Yes. Okay, great.
37:23 Thanks a lot. I appreciate it. Thank you. We have reached the end of the question and answer session. Mr. Michel, I would now like to turn the floor back over to you for closing comments.
37:36 Well, thank you all for taking the time today to join the call. In closing, I will reiterate that I am thrilled to have joined the team here at Delcath and stay together with that team. You know, we intend to build a world-class interventional oncology company. Thank you for your support. Goodbye. Ladies and gentlemen this does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a wonderful day.
Follow Delcath Systems, Inc. into a list and get an email when it puts out news.
Host, Hayden Vesta Relations
Chief Executive Officer
Principal Accounting Officer
Equity Research Analyst, Roth Capital
Equity Research Analyst, Laidlaw & Company
Vice President Medical Affairs
Chief Operating Officer